Podcasts about joint ventures

- DOJ Fain Probe May Extend UAW Federal Oversight - Honda Shrinks in China but Extends GAC Partnership - Honda Considers Building New North American Plant - China Auto Suppliers Pivot to Booming Motorcycle Sector - U.S. EV Sales Stabilize in May - Electric Cars Outsell All Other Powertrains in Germany - China Quietly Restricts Rare Earth Exports to U.S. - Struggling Aston Martin in Talks for New Liquidity

- DOJ Fain Probe May Extend UAW Federal Oversight - Honda Shrinks in China but Extends GAC Partnership - Honda Considers Building New North American Plant - China Auto Suppliers Pivot to Booming Motorcycle Sector - U.S. EV Sales Stabilize in May - Electric Cars Outsell All Other Powertrains in Germany - China Quietly Restricts Rare Earth Exports to U.S. - Struggling Aston Martin in Talks for New Liquidity

In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD (academic clinical lecturer in rheumatology, University of Leeds), and Rihards Buss, MD (consultant rheumatologist, Freeman Hospital, Newcastle), record a post-EULAR 2026 debrief, working through the abstracts each identified as the meeting's most consequential. The conversation spans cellular therapies in autoimmune disease, proteomic biomarkers for treatment selection in RA, a landmark head-to-head trial in psoriatic arthritis, evolving classification criteria for axial spondyloarthritis, and the first phase III randomized controlled trial of a JAK inhibitor in polymyalgia rheumatica.Studies featured in this episode include: AB-101 Allogeneic NK Cell Therapy in Rheumatologic Diseases (LB0003)  CARLYSLE: Obe-Cel CAR T in Severe Refractory SLE (OP0341) Ex Vivo Proteomic Signatures of JAK and TNF Inhibitors Predict Treatment Response in RA (OP048) BE BOLD: Bimekizumab vs Risankizumab in PsA (LB0001) 2025 ASAS-SPARTAN Revised AxSpA Classification Criteria (OP0236, OP0239, POS0190, POS1341) JAK-SPARE: Baricitinib in Early Polymyalgia Rheumatica (LB0005) Click here to read more and watch the full video at RheumatologyLive.

Ross has been taking notes and wants a follow up conversation on the ways that physical play creates an entry point for social relationships. Tom points out how joint ventures in the physical world create openings for friendship—bumping cars, filling big buckets with sand. Joey is reminded of recent statue game where physical play was a path to quickly forming relationships. Mike wonders if physical games are more like choreography than a written script. In the end, do we just need more time for play?

Paul Moore is the principal at Wellings Capital, based in Lynchburg Virginia. On today's show we're talking about how the investment thesis has changed in response to market conditions. To connect with Paul visit https://www.wellingscapital.com/They also have a number of resourcesincluding their due diligence checklist available on their resources page at https://www.wellingscapital.com/resources-----------------**Real Estate Espresso Podcast:** Spotify: [The Real Estate Espresso Podcast](https://open.spotify.com/show/3GvtwRmTq4r3es8cbw8jW0?si=c75ea506a6694ef1)   iTunes: [The Real Estate Espresso Podcast](https://podcasts.apple.com/ca/podcast/the-real-estate-espresso-podcast/id1340482613)   Website: [www.victorjm.com](http://www.victorjm.com)   LinkedIn: [Victor Menasce](http://www.linkedin.com/in/vmenasce)   YouTube: [The Real Estate Espresso Podcast](http://www.youtube.com/@victorjmenasce6734)   Facebook: [www.facebook.com/realestateespresso](http://www.facebook.com/realestateespresso)   Email: [podcast@victorjm.com](mailto:podcast@victorjm.com)  **Y Street Capital:** Website: [www.ystreetcapital.com](http://www.ystreetcapital.com)   Facebook: [www.facebook.com/YStreetCapital](https://www.facebook.com/YStreetCapital)   Instagram: [@ystreetcapital](http://www.instagram.com/ystreetcapital)  

If you're trying to win federal contracts with no past performance, this episode breaks down exactly how 8(a) joint ventures solve that problem. A govcon consultant walks through how he used JV partnerships and tribal 8(a) entities to win sole source work before his own company had a track record, and why relationships built over decades still beat any cold outreach strategy. Whether you're new to federal contracting or scaling an 8(a) firm, this is a real-world playbook for bridging the past performance gap. How to use JV partnerships to win sole source contracts before you have your own past performance Why tribal 8(a) entities like Spokane offer unique advantages for forming joint ventures How SBA's three-project rule determines how long an 8(a) JV can last What contracting officers and capability statements look for from a new 8(a) company Why decades-long relationships outperform cold pitches when finding JV partners EPISODE CHAPTERS: 0:00 - Mindy AI introduction and federal opportunity research 0:30 - Starting a new tribal 8a company from scratch 1:36 - Building capability statements and attending industry conferences 2:48 - Using JV and teaming partners before getting your own 8a 3:52 - Building past performance through JV projects over time 4:42 - How relationships lead to forming joint venture partnerships 6:03 - Negotiating pay and structuring the tribal 8a business plan 7:03 - Using JV past performance versus your own capability statement 8:18 - SBA three project rule and how long a JV lasts 9:21 - Keeping JV partners busy with self-performed work Mindy gives you the federal opportunities, agency signals, recompete intel, and pursuit briefs that tell you not just what contracts exist, but which ones to chase and how to win them. Sign up for free Daily Alerts and get opportunities delivered to your inbox before the day starts.

Bloomberg reported that Verizon and BT plan a joint venture combining their international enterprise units. The move would consolidate managed network services across multiple regions and could offer single-contract models for multinational customers. Regulatory approvals will likely be required in the United Kingdom, the United States, and other jurisdictions, with reviews focused on competition, security, and data residency. Integration will involve aligning OSS and BSS systems, product catalogs, and support workflows, creating potential migration risk. Customers should audit contracts, confirm assignment and SLA terms, and evaluate secondary providers for critical routes. Partners and vendors should prepare for centralized procurement and larger, consolidated bids for networking and cloud connectivity solutions.Learn more on this news by visiting us at: https://greyjournal.net/news/ Hosted on Acast. See acast.com/privacy for more information.

Shaping a government solicitation before the RFP drops is one of the most powerful competitive moves a small business can make and in this episode, Ryan Atencio walks through a live sources sought response strategy designed to nudge an active DoD training requirement toward a small business set-aside on Seaport Next Generation. This is real BD strategy in action, not theory. How to structure a sources sought response that recommends minimum requirements, acquisition strategy, and contract type all designed to eliminate low-price technically acceptable (LPTA) races to the bottom and filter out unqualified competitors Why joint venturing with the large business incumbent before the solicitation drops is the smartest teaming play a small business can make, and how to position that JV as a zero-risk transition solution for the contracting officer The staffing and recruiting mindset that drives wins in professional services contracting why putting the right people in seats is the only skill that truly matters for service contract capture How to use past performance from elite DoD customers like Naval Special Warfare (SEAL Teams) to build confidence with risk-averse contracting officers who hate change Why Eric prices every bid as if it is LPTA regardless of contract type and how that discipline keeps him competitive even when best-value trade-off evaluations are in play EPISODE CHAPTERS: 0:00 - Introducing Mindy AI and the federal research gap 0:30 - Welcome to the Federal Help Center podcast 0:52 - Seaport NxG strategy to cut out LPTA competition 1:20 - Why staffing and recruiting wins all service contracts 1:50 - Using elite past performance to build contracting officer confidence 2:48 - Why customers want the incumbent and how to neutralize that 3:17 - Joint venturing with T3i as a zero-risk transition play 4:17 - Writing industry recommendations that shape the requirement 5:14 - Pushing the set-aside, contract type, and NAICS strategy 5:39 - Pricing everything like LPTA even on best-value awards 6:36 - Adding specialized capabilities like UAS and pyro to the requirement 8:03 - Firm fixed price versus time and materials risk explained 9:55 - Final thoughts on small business set-aside advantages Mindy gives you the federal opportunities, agency signals, recompete intel, and pursuit briefs that tell you not just what contracts exist, but which ones to chase and how to win them. Sign up for free Daily Alerts and get opportunities delivered to your inbox before the day starts.

In this episode of Joint Ventures, host Rihards Buss, MD, consultant rheumatologist, Freeman Hospital, Newcastle, sits down with Sarah Dyball, MBBS, PhD, academic clinical lecturer, Centre for Musculoskeletal Research, University of Manchester, and Kate Harnden, MBChB, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, at the European Alliance of Associations for Rheumatology (EULAR) 2026 annual congress in London.Click here to watch the episode.

The therapeutic framework for systemic sclerosis is undergoing a fundamental reorientation, moving away from managing visible fibrotic sequelae toward targeting the autoantibody-driven mechanisms believed to initiate and propagate disease.On a recent episode of Joint Ventures recorded live at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress in London, host Jack Arnold, MBBS, PhD, of the University of Leeds, spoke with Vishal Kakkar, MD, also of the University of Leeds and a specialist in scleroderma, about the most consequential data emerging from the congress.Click here to watch the episode.

In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, academic clinical lecturer in rheumatology, University of Leeds, was joined at the European Alliance of Associations for Rheumatology (EULAR) 2026 annual congress in London by Laurence Duquenne, MD, a rheumatology researcher, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, an investigator on one of the meeting's standout studies to examine whether baseline naïve CD4+ T cell frequency can identify which newly diagnosed patients with rheumatoid arthritis (RA) are unlikely to respond to methotrexate monotherapy, and whether adding a biologic at the outset can close that gap.Click here to watch the episode.

This episode recorded live at the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference features Gary Herschman, Healthcare Transactions Shareholder, Baker Donelson, and Dana Jacoby, President & CEO, Vector Medical Group. Here, they discuss how joint ventures and strategic partnerships are evolving across musculoskeletal care and explore the growing role of physicians, hospitals, private equity, payers, and ASC operators in shaping future care models, governance structures, and value creation strategies.This episode is sponsored by Baker Donelson.

This episode recorded live at the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference features Gary Herschman, Healthcare Transactions Shareholder, Baker Donelson, and Dana Jacoby, President & CEO, Vector Medical Group. Here, they discuss how joint ventures and strategic partnerships are evolving across musculoskeletal care and explore the growing role of physicians, hospitals, private equity, payers, and ASC operators in shaping future care models, governance structures, and value creation strategies.This episode is sponsored by Baker Donelson.

Jetzt bei Kraken anmelden und 30 EUR Bonus erhalten: https://bit.ly/kraken-bonusThemen & Timestamps:00:00 Begrüssung und Themenüberblick00:38 Bitcoin-Funding-Rate und der Weg zu 70'000 Dollar03:08 KI-Agenten als Treiber des nächsten Bullruns04:53 Trump unterzeichnet Executive Order zu Quantencomputern06:29 Neues Staking- und Mining-Steuergesetz in den USA08:32 Partnerschaft zwischen ICE und OKEx10:32 Binance, die MiCA-Lizenz und das Eurotrading in Europa

We hebben het over Kevin Warsh, kersverse baas van de Fed. Op zijn eerste persconferentie maakte hij duidelijk dat het anders moet. De afgelopen vijf jaar heeft de Amerikaanse centrale bank de doelstelling niet gehaald en dat gaat hij nu anders doen. De Fed gaat op de schop. Er komen vijf werkgroepen die onderzoek wat er moet veranderen. Eén ding is al gelijk aangepast: de schriftelijk verklaring. Die is drastisch ingekort. Alleen doet hij niet wat hij (van president Trump) moet doen en dat is de rente verlagen. Sterker nog, die gaat dit jaar zo goed als zeker omhoog. Deze aflevering kijken we wat dit alles betekent voor jou en of hij jou óók teleurstelt. Tim Cook komt ook voorbij. De vertrekkend ceo van Apple kwam met slecht nieuws voor klanten. De prijzen moeten omhoog, want de inkoop van chips is veel te duur geworden. Opvallend, want Apple was een van de laatste technologiebedrijven die het tekort aan geheugenchips juist de baas bleef. We hebben het ook over de beleggersdag van Besi. Daar is voor ons Jordy Beuving van De Aandeelhouder. Hij vertelt waarom Besi zijn omzet- en winstdoel flink verhoogt en vertelt meer over de orders voor hun paradepaardje. Verder ook aandacht voor Box 3, de Iran-deal en Maserati. Te gast: Hans Oudshoorn van Saxo (die ook meer vertelt over investeren in netcongestie) BNR Beurs is een journalistiek onafhankelijke productie, mede mogelijk gemaakt door Saxo. Over de makers: Jelle Maasbach is presentator van BNR Beurs en freelance financieel journalist. Zijn favoriete aandeel om over te praten is Disney, maar daar lijkt hij de enige in te zijn. Sinds de eerste uitzending van BNR Beurs is 'ie er bij. Maxim van Mil is presentator van BNR Beurs en journalist bij BNR, waar hij zich focust op de financiële markten en ontwikkelingen in de tech-wereld. Je krijgt hem het meest enthousiast als hij kan praten over ASML, of oer-Hollandse bedrijven zoals Ahold of ABN Amro. Jorik Simonides is presentator van BNR Beurs, economieredacteur en verslaggever bij BNR. Hij wordt er vooral blij van als het een keer níet over AI gaat. Je hoort hem ook in de BNR-podcast Moerdijk: dorp van de rekening. Milou Brand is presentator van BNR Beurs, freelance podcastmaker en columnist bij het Financieele Dagblad. Jochem Visser is presentator van BNR Beurs, maakt Beursnerd XL en is redacteur bij de podcast Onder Curatoren. Vraag hem naar obscure zaken op financiële markten en hij vertelt je waarom het eigenlijk nóg leuker is dan je al dacht. Over de podcast: Met BNR Beurs ga je altijd voorbereid de nieuwe beursdag in. We praten je in een kleine 25 minuten bij over alle laatste ontwikkelingen op de handelsvloer. We blijven niet alleen bij de AEX of Wall Street, maar vertellen je ook waar nog meer kansen liggen. En we houden het niet bij de cijfers, maar zoeken ook iedere dag voor je naar duiding van scherpe gasten en experts. Of je nu een ervaren belegger bent of net begint met je eerste stappen op de beurs, de podcast biedt waardevolle inzichten voor je beleggingsstrategie. Door de focus op zowel de korte termijn als de lange termijn, helpt BNR Beurs luisteraars om de ruis van de markt te scheiden van de essentie. Van Musk tot Microsoft en van Ahold tot ASML. Wij vertellen je wat beleggers bezighoudt, wie de markten in beweging zet en wat dat betekent voor jouw beleggingsportefeuille.See omnystudio.com/listener for privacy information.

We hebben het over Kevin Warsh, kersverse baas van de Fed. Op zijn eerste persconferentie maakte hij duidelijk dat het anders moet. De afgelopen vijf jaar heeft de Amerikaanse centrale bank de doelstelling niet gehaald en dat gaat hij nu anders doen. De Fed gaat op de schop. Er komen vijf werkgroepen die onderzoek wat er moet veranderen. Eén ding is al gelijk aangepast: de schriftelijk verklaring. Die is drastisch ingekort. Alleen doet hij niet wat hij (van president Trump) moet doen en dat is de rente verlagen. Sterker nog, die gaat dit jaar zo goed als zeker omhoog. Deze aflevering kijken we wat dit alles betekent voor jou en of hij jou óók teleurstelt. Tim Cook komt ook voorbij. De vertrekkend ceo van Apple kwam met slecht nieuws voor klanten. De prijzen moeten omhoog, want de inkoop van chips is veel te duur geworden. Opvallend, want Apple was een van de laatste technologiebedrijven die het tekort aan geheugenchips juist de baas bleef. We hebben het ook over de beleggersdag van Besi. Daar is voor ons Jordy Beuving van De Aandeelhouder. Hij vertelt waarom Besi zijn omzet- en winstdoel flink verhoogt en vertelt meer over de orders voor hun paradepaardje. Verder ook aandacht voor Box 3, de Iran-deal en Maserati. Te gast: Hans Oudshoorn van Saxo (die ook meer vertelt over investeren in netcongestie) BNR Beurs is een journalistiek onafhankelijke productie, mede mogelijk gemaakt door Saxo. Over de makers: Jelle Maasbach is presentator van BNR Beurs en freelance financieel journalist. Zijn favoriete aandeel om over te praten is Disney, maar daar lijkt hij de enige in te zijn. Sinds de eerste uitzending van BNR Beurs is 'ie er bij. Maxim van Mil is presentator van BNR Beurs en journalist bij BNR, waar hij zich focust op de financiële markten en ontwikkelingen in de tech-wereld. Je krijgt hem het meest enthousiast als hij kan praten over ASML, of oer-Hollandse bedrijven zoals Ahold of ABN Amro. Jorik Simonides is presentator van BNR Beurs, economieredacteur en verslaggever bij BNR. Hij wordt er vooral blij van als het een keer níet over AI gaat. Je hoort hem ook in de BNR-podcast Moerdijk: dorp van de rekening. Milou Brand is presentator van BNR Beurs, freelance podcastmaker en columnist bij het Financieele Dagblad. Jochem Visser is presentator van BNR Beurs, maakt Beursnerd XL en is redacteur bij de podcast Onder Curatoren. Vraag hem naar obscure zaken op financiële markten en hij vertelt je waarom het eigenlijk nóg leuker is dan je al dacht. Over de podcast: Met BNR Beurs ga je altijd voorbereid de nieuwe beursdag in. We praten je in een kleine 25 minuten bij over alle laatste ontwikkelingen op de handelsvloer. We blijven niet alleen bij de AEX of Wall Street, maar vertellen je ook waar nog meer kansen liggen. En we houden het niet bij de cijfers, maar zoeken ook iedere dag voor je naar duiding van scherpe gasten en experts. Of je nu een ervaren belegger bent of net begint met je eerste stappen op de beurs, de podcast biedt waardevolle inzichten voor je beleggingsstrategie. Door de focus op zowel de korte termijn als de lange termijn, helpt BNR Beurs luisteraars om de ruis van de markt te scheiden van de essentie. Van Musk tot Microsoft en van Ahold tot ASML. Wij vertellen je wat beleggers bezighoudt, wie de markten in beweging zet en wat dat betekent voor jouw beleggingsportefeuille.See omnystudio.com/listener for privacy information.

Corporate India is bracing for major leadership and structural shifts. Reports suggest former RBI Deputy Governor Rajeshwar Rao is a top contender for the HDFC Bank chairman role. Simultaneously, the Dixon-Vivo JV is nearing regulatory approval, signaling a major boost for domestic electronics manufacturing. Get the strategic briefing here.

Corporate India is bracing for major leadership and structural shifts. Reports suggest former RBI Deputy Governor Rajeshwar Rao is a top contender for the HDFC Bank chairman role. Simultaneously, the Dixon-Vivo JV is nearing regulatory approval, signaling a major boost for domestic electronics manufacturing. Get the strategic briefing here.

Corporate India is bracing for major leadership and structural shifts. Reports suggest former RBI Deputy Governor Rajeshwar Rao is a top contender for the HDFC Bank chairman role. Simultaneously, the Dixon-Vivo JV is nearing regulatory approval, signaling a major boost for domestic electronics manufacturing. Get the strategic briefing here.

Comments/ideas: ACFpod@outlook.comChina's carbon market is already the world's largest, and it's about to get far more complex. Leading market expert Jeff Huang has a front-row seat to what's coming: absolute emissions caps replacing the old intensity targets, carbon auctioning arriving in steel, cement and aluminium, and Hong Kong quietly positioning itself as the trading hub that connects all of it to global markets. If you're watching how carbon pricing shapes capital flows and CBAM compliance, this episode is worth your time.Reference: AEX Holdings. Op-ed sample - Beyond critical mass (China Daily, 16 January 2026)ABOUT JEFF: Jeff Huang is founder & CEO of AEX Markets based in Hong Kong. He is former Managing Director Greater China of the Intercontinental Exchange (ICE), VP Asia for Chicago Climate Exchange (CCX), and was appointed Chief Advisor for Chongqing Gas Exchange. He's also founder of AsiaREC Limited, a non-profit carbon standard in Hong Kong. Jeff has more than 10 years of experience in cross-border M&A, Joint Ventures and futures markets in the United States, covering spaces including exchanges, futures companies, financial software infrastructure, etc. Prominent deals he has led include the creation of the Tianjin Climate Exchange (a joint venture between CCX and CNPC/PetroChina), forming a JV for futures brokerage between Citic and Calyon (SocGen) and a fintech acquisition for SunGard.Recommendation: The Great Game by Peter Hopkirk: A gripping historical account of the 19th-century imperial rivalry between the British and Russian empires as they vied for supremacy in Central Asia.HOST, PRODUCTION, ARTWORK: Joseph Jacobelli  |  MUSIC: Ep76 onward excerpts from Vivaldi's La Follia, played by Luca Jacobelli.

Government contract joint ventures and teaming agreements can unlock multi-million dollar opportunities — but one compliance mistake can cost you your small business status before you ever perform a day of work. In this episode, govcon veteran David Rambhajan breaks down exactly how to structure partnerships the right way so you win bids, stay compliant, and never get blindsided by an affiliation ruling. Affiliation risk in prime-sub relationships — Learn why subcontracting too much work to a large business can trigger an SBA affiliation finding that strips your small business designation on a live solicitation. Teaming agreements vs. prime-sub contracts — Understand the critical difference between an informal subcontract and a formal teaming agreement, and when a teaming agreement actually reduces your affiliation exposure with the government. Using teaming agreements to unlock bonding capacity — David reveals how a six-month-old small business used a teaming partner's indemnification to secure a multi-million dollar bond — and what the compliance letter requirement means for your bid protest strategy. Joint venture structure and the 51% ownership rule — Discover why a large business holding even 49% of your JV can disqualify it as a small business — and the one exception under the SBA Mentor-Protégé Program that changes everything. SDVOSB set-asides vs. veteran-owned set-asides — David clarifies a common misconception: current set-asides target service-disabled veteran-owned businesses, not all veteran-owned businesses, and what a pending legislative change could mean for your competition pool. EPISODE CHAPTERS: 0:00 - Introduction to govcon partnership rules and risks 0:30 - Welcome to the Federal Help Center podcast with Eric Coffie 1:00 - Affiliation risk when subcontracting to large businesses 2:05 - Self-performance requirements in construction vs services 2:45 - Why clear expectations prevent teaming relationship failures 3:14 - How teaming agreements differ from prime-sub contracts 4:05 - Real story of a six-month-old business winning a bonded contract 5:09 - Teaming agreements and bond indemnification compliance letters 7:35 - When teaming with large businesses reduces affiliation exposure 9:02 - Joint ventures as separate legal entities with tax IDs 9:44 - The 51% ownership rule and large business JV disqualification 10:16 - Mentor-protégé program and the billion dollar JV bid story 12:09 - SDVOSB set-aside rules and the veteran-owned business distinction 13:07 - Final compliance takeaway and community call to action   Mindy gives you the federal opportunities, agency signals, recompete intel, and pursuit briefs that tell you not just what contracts exist, but which ones to chase and how to win them. Sign up for free Daily Alerts and get opportunities delivered to your inbox before the day starts.

In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, a consultant rheumatologist at Freeman Hospital, Newcastle, preview their unofficial countdown of the sessions, themes, and abstracts they are most excited about heading into the 2026 European Alliance of Associations for Rheumatology (EULAR) Annual Meeting in London, June 3–6, including:  Obesity, Weight Management, and Psoriatic Arthritis Sessions Personalized Medicine and Biomarkers in RMDs Sessions Fatigue and Quality of Life in Connective Tissue Disease Session Mitochondrial DNA and Interferon: Upstream Drivers of Autoimmunity Session Artificial Intelligence and Pattern Recognition in Rheumatology Sessions Axial Imaging in Axial Spondyloarthritis Session Head-to-Head Superiority Trials in RA and PsA Sessions CAR-T and CAR-NK Therapies: Efficacy, Limits, and What Comes Next Sessions

In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MBBS, a consultant rheumatologist at Freeman Hospital, dive into 2 emerging therapeutic strategies with the potential to reshape care for systemic lupus erythematosus (SLE) and psoriatic arthritis (PsA): Fc receptor blockade with nipocalimab and tyrosine kinase 2 (TYK2) inhibition with deucravacitinib, distinct pathways united by a shared goal of greater precision in immune modulation.

Introducing Joint Ventures — a new podcast exploring advances in rheumatologic disease and what they mean for real-world practice. Hosted by RheumatologyLive, the series is led by Jack Arnold, MBBS, PhD, and Rihards Buss, MBBS, 2 United Kingdom-based rheumatologists united by a shared interest in translating rapidly evolving science into thoughtful, patient-centered care.Joint Ventures is designed for rheumatologists and clinicians managing immune-mediated disease who are navigating an increasingly complex therapeutic landscape. Each episode will examine emerging evidence, new mechanisms of action, and shifting paradigms in rheumatology, with a focus on how these developments intersect with clinical reasoning, uncertainty, and long-term patient management.Arnold is an academic clinical lecturer in rheumatology at the Leeds Institute of Rheumatic and Musculoskeletal Medicine in University of Leeds, with research interests spanning systemic lupus erythematosus, clinical trials, and the application of deep learning in medicine. Buss is a consultant rheumatologist specializing in psoriatic arthritis at Newcastle's Freeman Hospital, with a particular focus on integrating new data into day-to-day clinical decision-making. 

In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, a consultant rheumatologist at Freeman Hospital, Newcastle, turn from osteoarthritis to the inflammatory arthritides — examining what early data in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and lupus can and cannot yet tell us about the role of GLP-1 receptor agonists in disease modification.“Everyone is talking about [GLP-1 RAs] and what it can do for our patients. Much more evidence is needed to be much more better understanding about increasing effects beyond weight loss is needed. And I think that evidence will be just coming out very rapidly, year by year… but I think this is not the case where we're going to wait for strong evidence, good quality RCT data before we start to start to use them,” Buss said.

In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, a consultant rheumatologist at Freeman Hospital, Newcastle, examine the growing evidence for GLP-1 receptor agonists in rheumatological disease — drugs originally developed for glycemic control that are now drawing serious attention as potential immunomodulators with implications across the specialty.The conversation opens by tracing the arc of GLP-1 agonist development, from exenatide's approval in 2005 through to semaglutide's landmark cardiovascular and renal data in the SELECT1 and FLOW2 trials, before turning to the question now quietly circulating in rheumatology clinics: are these drugs doing something beyond shifting weight?

In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, a consultant rheumatologist at Freeman Hospital, Newcastle, are joined by guest Lucy Carter, MBBS, PhD, a consultant rheumatologist at Newcastle upon Tyne NHS Foundation Trust and honorary clinical senior lecturer at Newcastle University, to examine nearly 2 decades of B cell–targeted therapy in rheumatic disease — a story that has proven considerably more complicated than its early promise suggested.Carter, Arnold, and Buss trace the mixed legacy of rituximab in lupus and Sjögren disease and examining how incomplete B cell depletion, BAFF-driven rebound, and trial design limitations may have contributed to disappointing early results. The discussion then turns to newer approaches such as obinutuzumab, whose positive REGENCY and ALLEGORY trial data in lupus nephritis and systemic lupus erythematosus suggest that deeper, more durable B cell depletion may improve outcomes, while emerging CAR-T data raise broader questions about the future role of intensive immune reprogramming in autoimmune disease.

In the second part of this Joint Ventures episode on B cell therapies in rheumatic disease, hosts Jack Arnold, MBBS, PhD, and Rihards Buss, MD, return with guest Lucy Carter, MBBS, PhD, to move beyond the question of how to deplete B cells and toward the more conceptually challenging problem of what happens after depletion — and whether ianalumab's dual mechanism of action represents the most rational answer yet developed.The episode examines the biologic rationale behind combining rituximab with belimumab, reviews the landmark NEPTUNUS Sjögren disease trials in which ianalumab became the first targeted therapy to meet a phase 3 primary endpoint in the disease, and discusses how emerging therapies may ultimately reshape treatment selection, steroid reduction strategies, and long-term management of autoimmune conditions including Sjögren disease and systemic lupus erythematosus.

In this episode, we dive deep into the promise and pitfalls of industrial AI with hands-on experts from a unique Volkswagen-Siemens joint venture. We challenge the hype around humanoid robots, discuss the practical impact of AI on factory design and operations, and uncover what truly drives value on the shop floor. Our guests share candid insights on scaling AI solutions, the role of synthetic data, and why safety and trust remain at the core of industrial automation. Join us as we separate fact from fiction and chart the path forward for intelligent manufacturing. If you're curious about the real impact of AI beyond the buzzwords, this conversation is for you.

French-Italian auto group Stellantis and China's Dongfeng have announced a plan to launch a joint venture based in Europe, with Stellantis having a 51 percent controlling stake. The deal would see Dongfeng's new electric models assembled at Stellantis's plant in western France to comply with the EU's new "Made in Europe" rule that requires 70 percent of EV content to be made locally. Also in the segment: one man in the US has turned a broken pink Barbie car into a solution to combat soaring fuel prices. 

Erfahre hier mehr über unseren Partner Scalable Capital - dem Broker mit einem der besten YouTube-Kanäle zu Aktien & Investments. https://www.youtube.com/@scalable.capital/videos Deutsche Software- und Rüstungsaktien erholen sich. Rheinmetall bekommt Milliarden-Auftrag. Grizzly Research mit Short-Report bei Ottobock. Blackstone und Google greifen Neocloud-Anbieter an. Agilysys meldet 17. Rekordquartal in Folge. Amer Sports hebt Prognose an. OHB (WKN: 593612) gründet mit Helsing ein Joint Venture für Bundeswehr-Aufklärungssatelliten. Milliardenschwere Aufträge winken, KKR hat sein Investment verzehnfacht. Aber das KGV von 130 ist sportlich. David Einhorn setzt auf Versant Media (WKN: A41RUQ), den Comcast-Spinoff. Schmelzendes Kabel-Eis, aber starke Digitalmarken wie Rotten Tomatoes und GolfNow. Unterbewertung durch Zwangsverkäufe nach Abspaltung? Diesen Podcast vom 20.05.2026, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this throwback episode from 2023 Alan revisits a long-standing "chip on his shoulder": the persistent and often unscientific demand for antibiotic premedication in joint replacement patients. Sparked by his own wife's hip surgery, Alan dives into the disconnect between evidence-based ADA/AAOS guidelines and the "premedicate for life" culture maintained by many orthopedic surgeons. With his signature wit and candid frustration, he explores the risks of antibiotic resistance, the myth of dental-induced bacteremia, and the awkward "middle man" position patients are forced into when dental and surgical philosophies collide. Some links from the show: "Meet the new guidelines. Same as the old guidelines" ADA joint premedication guidelines AAOS joint decision tree website AAOS premedication guidelines Join the Very Dental Facebook Group using one of these passwords: Timmerman, Paul, Bioclear, Hornbrook, Gary, McWethy, Papa Randy, Frank or Lipscomb!  The Very Dental Podcast network is and will remain free to download. If you'd like to support the shows you love at Very Dental then show a little love to the people that support us! We're proud to be supported by the folks at Net32! I'm a big fan of the Bioclear Method! I think you should give it a try and I've got a great offer to help you get on board! Use the exclusive Very Dental Podcast code VERYDENTAL8TON for 15% OFF your total Bioclear purchase, including Core Anterior and Posterior Four day courses, Black Triangle Certification, and all Bioclear products. Crazy Dental has everything you need from cotton rolls to equipment and everything in between and the best prices you'll find anywhere! If you head over to verydentalpodcast.com/crazy and use coupon code "VERYSHIP" you'll get free shipping on your order! Go save yourself some money and support the show all at the same time! The Wonderist Agency is basically a one stop shop for marketing your practice and your brand. From logo redesign to a full service marketing plan, the folks at Wonderist have you covered! Go check them out at verydentalpodcast.com/wonderist! Enova Illumination makes the very best in loupes and headlights, including their new ergonomic angled prism loupes! They also distribute loupe mounted cameras and even the amazing line of Zumax microscopes! If you want to help out the podcast while upping your magnification and headlight game, you need to head over to verydentalpodcast.com/enova to see their whole line of products! CAD-Ray offers the best service on a wide variety of digital scanners, printers, mills and even  their very own browser based design software, Clinux! CAD-Ray has been a huge supporter of the Very Dental Podcast Network and I can tell you that you'll get no better service on everything digital dentistry than the folks from CAD-Ray. Go check them out at verydentalpodcast.com/CADRay!

Das ist das KI-Update vom 06.05. 2026 unter anderem mit diesen Themen: Mistral veröffentlicht Medium 3.5 und Cloud-Funktionen OpenAI und Anthropic gründen milliardenschwere Joint Ventures Mit KI auf der Suche nach Arzneistoffen und Informatiker*innen sind die besseren Vibe-Coder === Anzeige / Sponsorenhinweis === Dieser Podcast wird von einem Sponsor unterstützt. Alle Infos zu unseren Werbepartnern findet ihr hier. https://wonderl.ink/%40heise-podcasts === Anzeige / Sponsorenhinweis Ende === Links zu allen Themen der heutigen Folge findet Ihr im Begleitartikel auf heise online: https://heise.de/-11283944 Weitere Links zu diesem Podast: https://www.heiseplus.de/audio https://www.heise.de/thema/KI-Update https://pro.heise.de/ki/ https://www.heise.de/newsletter/anmeldung.html?id=ki-update https://www.heise.de/thema/Kuenstliche-Intelligenz https://the-decoder.de/ https://www.ct.de/ki Eine neue Folge gibt es montags, mittwochs und freitags ab 15 Uhr.

Plus: Chip startup Cerebras Systems sets IPO price. And GameStop makes an unsolicited $56 billion offer to buy eBay. Imani Moise hosts. Learn more about your ad choices. Visit megaphone.fm/adchoices

Wayne and Gabby break down how they've added over $6M to their real estate portfolio in the last two years using joint ventures. They walk through a real deal they're currently closing, sharing lessons on negotiation, timing, and how investor behavior impacts outcomes. They also unpack a recent report on Edmonton real estate returns and explain what investors should actually take away from it.

Dov returns to the podcast to talk about his new masterclass, the importance of partnerships, and much more!

Send us Fan MailHow do billion-dollar investors evaluate deals and decide who to partner with? In this episode, panelists break down how family offices and institutional investors approach co-investments, joint ventures, and strategic partnerships.Learn how top investors assess sponsors, structure deals, and determine whether an opportunity strengthens their platform. This is essential listening for anyone structuring co-GP deals, raising capital, or looking to partner with family offices and private equity groups.If you want to connect with serious investors, build better partnerships, and access real deal flow—join us inside the Family Office Club.Our investor club offers 30 nationwide events a year, 10,000 registered investors, and 40 proprietary AI tools designed to help you raise capital faster and more effectively.

The Hilarious and Sexy New Film Will Be Coming to Theaters April 24! Winner of the Special Jury Prize at Sundance, TWO WOMEN is an irrepressible comedy about two mothers who refuse to settle for stagnant lives and instead pursue the joy they need to feel alive and fulfilled.   When neighbors Violette (Laurence Leboeuf) and Florence (Karine Gonthier-Hyndman) bond over the ennui of parenthood, they realize that the solution to reviving their joie de vivre may be in listening to their libidos. As the two start finding sex in unexpected places, they examine the larger unfulfilled needs that brought them to their current moment and choose to pursue a life of joy over compromise.   Director Chloé Robichaud captures the Montreal winter in sumptuous 35mm film; Screenwriter Catherine Léger has adapted her own stage play, itself an update of the 1970 Quebecoise classic Two Women in Gold. Sophie Nélisse, Juliette Gariépy, Mani Soleymanlou, and Félix Moati complete a stellar ensemble cast.   Wonderfully layered, empathetic, sexy, and fun, TWO WOMEN urges us to consider that life is not a straight line and to remember that there are infinite kinds of pleasure we can experience together if we simply allow ourselves to give in.   Connect: The Film and Director The Film: @twowomenmovie Director (Chloé Robichaud): @chloerobish The Stars Laurence Leboeuf (Violette): @lorleb Karine Gonthier-Hyndman (Florence): @pennybobette The Distribution Team Joint Venture: @jointventurefilm   About Joint Venture Joint Venture is an independent film studio that distributes each project by building coalitions with filmmakers, audiences, and partners across sectors. The company's release strategies are bespoke because an audience-centered, filmmaker-forward approach unlocks the greatest potential for each film. That's why it's a Joint Venture.

- China Likely on Major Restructuring Path - GM Pays $40 Million to Lure Tech Executive - Schaeffler Could Be Top Humanoid Supplier - VW Cutting Production Another 1 Million Units - Honda and Sony Scale Back JV Even More - Hyundai's 1st Compact IONIQ EV - Young Chinese Ditch German Luxury Brands - U.S. Interest in Chinese Cars Surges Via TikTok

- China Likely on Major Restructuring Path - GM Pays $40 Million to Lure Tech Executive - Schaeffler Could Be Top Humanoid Supplier - VW Cutting Production Another 1 Million Units - Honda and Sony Scale Back JV Even More - Hyundai's 1st Compact IONIQ EV - Young Chinese Ditch German Luxury Brands - U.S. Interest in Chinese Cars Surges Via TikTok

This episode recorded live at the Becker's 16th Annual Meeting features Ann Cornelius, Chief Revenue Officer, DASCO Home Medical Equipment. Here, she explores how DME joint ventures can reduce post acute leakage, improve care transitions from hospital to home, and support value based outcomes while enhancing patient experience and operational efficiency.This episode is sponsored by DASCO Home Medical Equipment,

In this episode, Geri Eaves, Vice President of Ambulatory Services, MedHQ, and Wes Battiste, Senior Advisor, Avanza Strategies, explore the rapid growth of ASC joint ventures and what drives their success. They discuss physician alignment, governance structures, and the importance of collaboration to deliver high-quality, cost-effective outpatient care.This episode is sponsored by MedHQ.

Trump declares victory after a last-minute ceasefire forces Iran to reopen the Strait of Hormuz, easing global oil disruptions and halting imminent U.S. strikes. With hundreds of ships still backed up, Trump proposes a controversial U.S.–Iran "joint venture" to secure the waterway and potentially manage transit operations together. As negotiations continue during the temporary truce, questions remain about whether this deal signals a true end to the conflict or just a pause before the next phase.   Become A Member http://youtube.com/timcastnews/join The Green Room - https://rumble.com/playlists/aa56qw_g-j0 BUY CAST BREW COFFEE TO FIGHT BACK - https://castbrew.com/ Join The Discord Server - https://timcast.com/join-us/ Hang Out With Tim Pool & Crew LIVE At - http://Youtube.com/TimcastIRL

- Honda Cancels Afeela EV Joint Venture with Sony - GM Repurposes Cruise Bolts for Super Cruise Testing - Stellantis Tickets Workers for Driving Rival Cars - BorgWarner Opens New EV Motor Plant in China - Chinese Steel Breakthrough Offers Lighter Car Components - Robert Bollinger Buys Back EV Startup For $250,000 - Cupra Debuts First 3D-Knit Zero Waste Car Seats - Renault Launches AI Personalized In-Car Radio Service

- Honda Cancels Afeela EV Joint Venture with Sony - GM Repurposes Cruise Bolts for Super Cruise Testing - Stellantis Tickets Workers for Driving Rival Cars - BorgWarner Opens New EV Motor Plant in China - Chinese Steel Breakthrough Offers Lighter Car Components - Robert Bollinger Buys Back EV Startup For $250,000 - Cupra Debuts First 3D-Knit Zero Waste Car Seats - Renault Launches AI Personalized In-Car Radio Service

Send us Fan MailWhat does it really take to go from $0 to billions in product sales?In this high-energy strategy session, I sit down with Kevin Harrington — original shark on Shark Tank, inventor of the infomercial, and founder behind 20+ companies that each surpassed $100M in revenue.This isn't theory. This is a tactical breakdown of how a real operator builds billion-dollar momentum.Kevin shares:• Why customer acquisition strategy matters more than your product• How Celsius went from a 22¢ stock to a $12B brand using influencer distribution• The “Tease, Please, Close” framework for irresistible pitch videos• Why lifetime customer value beats one-time sales every time• How to negotiate royalty deals that create long-term deal flow• The psychology behind closing high-stakes transactions• How to turn negotiations around so the other side sells you• Why fair deal structures lead to billion-dollar partnerships• The health, energy, and personal standards required to operate at high velocityWe also go deep on:Distribution as the ultimate moatStructuring deals that attract repeat partnersCreating exponential vs. geometric growthWhen and how to restructure agreementsPositioning yourself to see deals first — and at better valuationsKevin also shares behind-the-scenes lessons from building As Seen on TV, launching global infomercials across multiple continents, and scaling through downtime arbitrage in media.If you are a founder, investor, family office executive, or capital raiser, this episode is a masterclass in:Branding + Distribution + Deal Structure + Energy ManagementNo fluff. No theory. Just tactical insights from someone who has generated over $5B in product sales.If you want to operate at a centimillionaire level — this is required listening.https://familyoffices.com/

See omnystudio.com/listener for privacy information.